ArticleFrontiers in oncology2025
Network toxicological insights into DEHP exposure and thyroid cancer development and progression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify markers of di-2-ethylhexyl phthalate (DEHP) exposure associated with thyroid cancer occurrence and prognosis by integrating network toxicology and molecular docking. Expression profiles and clinical information were obtained from TCGA-THCA and five GEO datasets (GSE3467, GSE3678, GSE33630, GSE53157, and GSE60542). Venn diagram analysis revealed six overlapping genes (CYP1B1, ABCC3, KRT19, CUX2, GABRB2, and TNFSF15) between the combined dataset and DEHP's target genes. GO and KEGG enrichment analyses were conducted on these overlapping genes. Through multivariate COX regression model, it is clearly seen that CYP1B1, GABRB2 and TNFSF15 are highly expressed, and can basically be determined as candidate hub genes. Kaplan-Meier survival analysis indicated that the high-risk group had a significantly poorer prognosis (p < 0.05). Furthermore, prognostic ROC curves based on the GEO validation set demonstrated that CYP1B1, GABRB2, and TNFSF15 were significantly associated with thyroid cancer diagnosis (AUC exceeding 0.86). Finally, molecular docking was employed to visualize the interaction sites between DEHP and its target genes. In conclusion, this study provides novel targets for the prevention and treatment of thyroid cancer in the context of DEHP exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.